Accessibility Menu
Mangoceuticals logo

Mangoceuticals(NASDAQ) MGRX

Market Cap$9.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-99%
5 YearN/A
1 Year-67%
1 Month+31%
$0.55
+86.79%
+0.25Today
After hours$0.48-$0.07 (-12.64%)
Mangoceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.562026-07-31
Mangoceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.99%USD 0.522026-07-24
1 month+30.77%USD 0.432026-07-01
3 month+75.3%USD 0.322026-05-01
Year to date-24.72%USD 0.742025-12-31
1 year-66.84%USD 1.682025-07-31
3 year-97.44%USD 21.752023-08-01
Since inception-99.07%USD 60.002023-03-21

Mangoceuticals Financials at a Glance

Market Cap

$9.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$414.58K

Net Income (TTM)

-$19.21M

EPS (TTM)

-$1.62

P/E Ratio

-0.34

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.55

Volume

512,124,617.359

Open

$0.64

Previous Close

$0.56

Daily Range

$0.52 - $1.25

52-Week Range

$0.16 - $2.75

Estimated Earnings Date

May 19, 2026

MGRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mangoceuticals

Mangoceuticals helps men address health issues like erectile dysfunction and hair loss. Its online platform connects users with doctors for easy access to treatments. The company’s products aim to make men’s wellness more convenient and private.

Products and Services

  • Erectile Dysfunction (ED) Treatments: Prescription and compounded pills for men with ED, sold under the Mango brand.
  • Hair Loss Solutions: Topical and oral treatments for male hair loss, including Minoxidil and Finasteride.
  • Weight Management: Semaglutide-based products for men seeking to manage weight.
  • Hormone Therapy: Oral testosterone and hormone balance therapies for men with low testosterone or hormone imbalances.
  • Upcoming Skincare: Plant-based skin brightening product (Dermytol) intended to launch in the 3rd quarter of 2025.
  • Respiratory Illness Prevention: Patented technology in clinical trials for flu and avian flu prevention.

Growth and Expansion

  • Entered the UK and Mexico markets through subsidiaries in 2023 and 2024.
  • Signed a master distribution deal with Propre Energie for Dermytol in 2025.
  • Acquired patents for respiratory illness prevention and mushroom-based supplements in 2024.
  • Partnered with PrevenTech Solutions for global distribution of respiratory technology in 2025.
  • Launched new telemedicine platform in early 2025 to improve user experience.

What Makes Mangoceuticals Stand Out

Mangoceuticals uses a direct-to-consumer telemedicine model, connecting patients with doctors online. Its proprietary blends combine approved drugs and supplements for personalized care. The company holds patents and exclusive distribution rights for new wellness and prevention products.

Five Things You Need to Know

  • Q2 2025 revenue was $168,109, up 3.0% from Q2 2024.
  • Gross profit for Q2 2025 was $89,948, up 28.9% year-over-year.
  • Net loss for Q2 2025 was $5 million, up from $2 million in Q2 2024.
  • Cash used in operations for the first half of 2025 was $3.5 million.
  • As of June 2025, the company had $101,019 in cash and a $1.5 million working capital deficit.

Bottom Line

Mangoceuticals has expanded its product range and global reach since 2021. The company faces ongoing losses but continues to invest in new health solutions and digital access for men’s wellness.

AI Generated • Apr 16, 2026

Industry

Food and Staples Retailing

Sector

Consumer Staples

Employees

3

CEO

Jacob D. Cohen

Website

www.mangoceuticals.com

Headquarters

Dallas, TX 75248, US

MGRX Financials

Key Financial Metrics (TTM)

Gross Margin

52.42%

Operating Margin

-4203.81%

Net Income Margin

-4632.94%

Return on Equity

-120.71%

Return on Capital

-123.51%

Return on Assets

-132.93%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

-3.06%

Stock Overview

Market Cap

$9.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.17M

Volume

512.12M

Avg. Volume

10.61M

Financials (TTM)

Gross Profit

$217.32K

Operating Income

-$17.43M

EBITDA

-$17.50M

Operating Cash Flow

-$4.89M

Capital Expenditure

$0.00

Free Cash Flow

-$4.89M

Cash & ST Invst.

$174.56K

Total Debt

$294.02K

Mangoceuticals Performance Analysis

Mangoceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,939N/A
20232023-12-31USD 731,4938083.2%
20242024-12-31USD 615,873-15.8%
20252025-12-31USD 456,021-26.0%
Mangoceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3053.8%
Q32025-09-30-49.9%
Q42025-12-3112.0%
Q12026-03-31-28.1%
Mangoceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.7311213.1%
20232023-12-31USD -6.45272.7%
20242024-12-31USD -4.40-31.8%
20252025-12-31USD -2.17-50.8%
Mangoceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3048.7%
Q32025-09-30-27.8%
Q42025-12-3172.5%
Q12026-03-31-78.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$67.86K

-37.9%

Gross Profit

$29.00K

-53.3%

Gross Margin

42.73%

N/A

Market Cap

$9.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.19M

N/A

Employees

3

N/A

Net Income

-$3.40M

+29.7%

EBITDA

-$3.13M

+29.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$174.56K

+128.2%

Total Debt

$294.02K

+516.2%

Accounts Receivable

$20.06K

N/A

Inventory

$0.00

N/A

Long Term Debt

$236.97K

N/A

Short Term Debt

$57.06K

+19.6%

Return on Assets

-1.33%

N/A

Return on Invested Capital

-1.27%

N/A

Free Cash Flow

-$1.31M

+42.4%

Operating Cash Flow

-$1.31M

+42.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FEMYFemasys Inc.
$2.86-1.72%
ENTOEntero Therapeutics, Inc.
$2.85-5.00%
CASICASI Pharmaceuticals, Inc.
$0.15+3.08%
CLSDClearside Biomedical, Inc.
$0.41+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About MGRX

What is the current price of Mangoceuticals?

Mangoceuticals is trading at $0.56 per share.

What is the 52-week range for Mangoceuticals?

Over the past 52 weeks, Mangoceuticals has traded between $0.16 and $2.75.

How much debt does Mangoceuticals have?

As of the most recent reporting period, Mangoceuticals reported total debt of $294.02K.

How much cash does Mangoceuticals have on hand?

Mangoceuticals reported $174.56K in cash and cash equivalents in its most recent financial results.

What is Mangoceuticals’s dividend yield?

Mangoceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services